Nilotinib Shows Early Promise for Parkinson's Disease

Share this content:
Nilotinib Shows Early Promise for Parkinson's Disease
Nilotinib Shows Early Promise for Parkinson's Disease

WEDNESDAY, July 13, 2016 (HealthDay News) -- A drug used to treat leukemia, nilotinib, has shown initial signs of promise for advanced cases of Parkinson's disease, according to a study published online July 11 in the Journal of Parkinson's Disease.

Charbel Moussa, M.D., Ph.D., assistant professor of neurology at the Georgetown University Medical Center in Washington, D.C., and colleagues had 12 patients with either Parkinson's disease dementia or dementia with Lewy bodies take low doses of nilotinib every day for six months.

One patient had to withdraw after one month because of heart complications. But the drug was well tolerated in the remaining patients, Moussa told HealthDay. The researchers found that nilotinib was detectable in the cerebrospinal fluid (CSF) and appeared to engage the target Abl. Patients typically showed some improvement in both physical symptoms and cognitive difficulties.

"We also obtained preliminary evidence of changes in dopamine metabolism in the CSF following treatment with nilotinib. However, the participants did not constitute a homogenous cohort, and there were large baseline differences in dopamine metabolite levels, making a definitive interpretation of these results difficult," the authors write. "Taken together, the data suggest that it is warranted to move forward with clinical trials to determine an appropriate therapeutic dose and evaluate nilotinib effects in larger, randomized, double-blinded, placebo-controlled trials."

Moussa is listed as an inventor on a Georgetown University intellectual property patent application to use nilotinib for the treatment of neurodegenerative diseases.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »